enGene Therapeutics Inc ENGN

1.96 0.04 2.08% as of 25 Sep
Market cap
$128.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jul '26 Apr '26 Jan '26 Oct '25 Older periods
Current Ratio
10.21 12.57 11.75 6.30

+8 more quarters

Net Debt/EBITDA
7.07 7.24 7.96 4.49
Debt/Assets
8.72% 8.10% 7.34% 6.92%
Debt/Equity
0.11 0.10 0.09 0.09
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.58 1.01 0.97 0.66
Capex/Depreciation
0.00 0.31 0.38 1.74
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.27) (0.44) (0.43) (0.50)
Cash per Share
3.82 3.71 4.10 3.79
Shareholders Equity per Share
3.30 3.66 4.19 3.28
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
3.30 3.66 4.19 3.28
Free Cash Flow
(18.95) (30.60) (29.06) (25.40)
Working Capital
250.69 248.52 264.61 169.41
Capital Expenditures
0.00 (0.10) (0.15) (0.44)
Net Current Asset Value
219.87 217.64 233.65 147.63
Other line items
Quick Ratio
9.83 12.07 11.26 6.09
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.27) (0.44) (0.43) (0.49)
Capex per Share
0.00 0.00 0.00 (0.01)
Average Receivables
0.84 0.68 0.81 0.63
Average Payables
2.46 1.68 2.52 4.05
Average Assets
266.94 287.09 311.52 266.32
Average Common Equity
215.48 241.23 265.75 220.16
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates